hmb002
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2022 (NCT05491135)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- HepatocyteTissue restoration
Hepatocyte tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06754852 | Phase 1/Phase 2 (Phase 2) | Feb 6, 2025 | Hemab ApS |
| NCT05491135 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Medical Research Council, University of London |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hemab ApS | For profit | 1 | 1 | 1 | 2025 |
| Medical Research Council | Government | 1 | 0 | 1 | 2022 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1